Download PDF
TumorDiagnostik & Therapie 2018; 39(09): 595-599
DOI: 10.1055/a-0754-4796
Thieme Onkologie aktuell
© Georg Thieme Verlag KG Stuttgart · New York

Statine als Therapie bei Lebererkrankungen?

Statins as a therapy of chronic liver disease?
Tilman Sauerbruch
  Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Germany
,
Robert Schierwagen
  Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Germany
,
Jonel Trebicka
  Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
26 October 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Statine vermindern die Cholesterinkonzentration im Plasma und senken damit das Risiko der koronaren Herzerkrankung. Darüber hinaus haben sie weitere sogenannte pleiotrope Effekte. Es gibt Hinweise, dass sich dies bei verschiedenen Lebererkrankungen positiv auswirken könnte.

Abstract

Statins have proven effects in the primary and secondary prevention of coronary disease. Besides lowering LDL-cholesterol beneficial pleiotropic consequences of statin therapy are increasingly discussed. Retrospective analyses of large cohort studies have shown favorable effects on the sequels of chronic viral induced liver disease and of non alcoholic fatty liver disease. These findings are substantiated by experimental work showing that statins reduce inflammation, fibrosis and proliferation in the diseased liver. Prospective controlled trials are necessary to elucidate whether, when and where statins have a role in the therapeutic armamentarium for liver disease.

Schlüsselwörter

Statine - chronische Lebererkrankungen - Leberzirrhose - Therapie

Key words

statins - chronic liver disease - liver cirrhosis - therapy
 

  • Literatur

  • 1 Schwabe U, Paffrath D. Arzneiverordnungs-Report 2016. Springer-Verlag; 2016
    PubMedGoogle Scholar
  • 2 Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10
    CrossrefPubMedGoogle Scholar
  • 3 Kohl NE, Mosser SD, deSolms SJ. et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993; 260: 1934-1937
    CrossrefPubMedGoogle Scholar
  • 4 Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res 2017; 120: 229-243
    CrossrefPubMedGoogle Scholar
  • 5 Russo MW, Hoofnagle JH, Gu J. et al. The Spectrum of Statin Hepatotoxicity: Experience of the Drug Induced Liver Injury Network. Hepatology 2014; 60: 679-686
    CrossrefPubMedGoogle Scholar
  • 6 Chalasani N, Aljadhey H, Kesterson J. et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-1292
    CrossrefPubMedGoogle Scholar
  • 7 Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig Liver Dis 2006; 38: 772-777
    CrossrefPubMedGoogle Scholar
  • 8 Athyros VG, Tziomalos K, Gossios TD. et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-1922
    CrossrefPubMedGoogle Scholar
  • 9 Kargiotis K, Athyros VG, Giouleme O. et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21: 7860-7868
    CrossrefPubMedGoogle Scholar
  • 10 Dongiovanni P, Petta S, Mannisto V. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology 2015; 63: 705-712
    CrossrefPubMedGoogle Scholar
  • 11 Nascimbeni F, Aron-Wisnewsky J, Pais R. et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2016; 3: e000075
    CrossrefPubMedGoogle Scholar
  • 12 Huang YW, Lee CL, Yang SS. et al. Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. Am J Gastroenterol 2016; 111: 976-985
    CrossrefPubMedGoogle Scholar
  • 13 Chang FM, Wang YP, Lang HC. et al. Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study. Hepatology 2017; DOI: 10.1002/hep.29172.
    CrossrefPubMedGoogle Scholar
  • 14 Simon TG, Bonilla H, Yan P. et al. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology 2016; 64: 47-57
    CrossrefPubMedGoogle Scholar
  • 15 Mohanty A, Tate JP, Garcia-Tsao G. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. Gastroenterology 2016; 150: 430-440
    CrossrefPubMedGoogle Scholar
  • 16 Oliver NT, Hartman CM, Kramer JR. et al. Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals. AIDS 2016 in press
    PubMedGoogle Scholar
  • 17 van der Meer AJ, Veldt BJ, Feld JJ. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593
    CrossrefPubMedGoogle Scholar
  • 18 Trebicka J, Hennenberg M, Laleman W. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46: 242-253
    CrossrefPubMedGoogle Scholar
  • 19 Uschner FE, Ranabhat G, Choi SS. et al. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep 2015; 5: 14573
    CrossrefPubMedGoogle Scholar
  • 20 Zafra C, Abraldes JG, Turnes J. et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126: 749-755
    CrossrefPubMedGoogle Scholar
  • 21 Abraldes JG, Albillos A, Bañares R. et al. Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. Gastroenterology 2009; 136: 1651-1658
    CrossrefPubMedGoogle Scholar
  • 22 Pollo-Flores P, Soldan M, Santos UC. et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. Dig Liver Dis 2015; 47: 957-963
    CrossrefPubMedGoogle Scholar
  • 23 Abraldes JG, Villanueva C, Aracil C. et al. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology 2016; 150: 1160-1170
    CrossrefPubMedGoogle Scholar
  • 24 du Souich P, Roederer G, Dufour R. Myotoxicity of statins: Mechanism of action. Pharmacol Ther 2017; 175: 1-16
    CrossrefPubMedGoogle Scholar
  • 25 Rodríguez S, Raurell I, Torres-Arauz M. et al. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats. Sci Rep 2017; 7 DOI: 40461.
    CrossrefPubMedGoogle Scholar
  • 26 Hsiang JC, Wong GLH, Tse YK. et al. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. J Hepatol 2015; 63: 1190-1197
    CrossrefPubMedGoogle Scholar
  • 27 Singh S, Singh PP, Singh AG. et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144: 323-332
    CrossrefPubMedGoogle Scholar
  • 28 Graf H, Jüngst C, Straub G. et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 2008; 78: 34-38
    CrossrefPubMedGoogle Scholar
  • 29 Kawata S, Yamasaki E, Nagase T. et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84: 886-891
    PubMedGoogle Scholar
  • 30 Higashi T, Hayashi H, Kitano Y. et al. Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma. Med Oncol 2016; 33: 123
    CrossrefPubMedGoogle Scholar
  • 31 Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792-1802
    CrossrefPubMedGoogle Scholar
  • 32 Emberson JR, Kearney PM. CholesterolTreatment Trialists’ (CTT) Collaboration. et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175000 people in 27 randomised trials of statin therapy. PLoS ONE. 2012 7. e29849
    PubMedGoogle Scholar
  • 33 Ray KK, Seshasai SRK, Erqou S. et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65229 participants. Arch Intern Med 2010; 170: 1024-1031
    CrossrefPubMedGoogle Scholar
  • 34 Trebicka J, Hennenberg M, Odenthal M. et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010; 53: 702-712
    CrossrefPubMedGoogle Scholar
  • 35 Klein S, Klösel J, Schierwagen R. et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest 2012; 92: 1440-1450
    PubMedGoogle Scholar
  • 36 Schierwagen R, Maybüchen L, Hittatiya K. et al. Statins improve NASH via inhibition of RhoA and Ras. Am J Physiol Gastrointest Liver Physiol 2016; 311 (04) G724-G733
    CrossrefPubMedGoogle Scholar
  • 37 Sutter AP, Maaser K, Höpfner M. et al. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005; 43: 808-816
    CrossrefPubMedGoogle Scholar
  • 38 Marrone G, Maeso-Díaz R, García-Cardena G. et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 2015; 64: 1434-1443
    CrossrefPubMedGoogle Scholar
  • 39 Zhou YY, Zhu GQ, Wang Y. et al. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget 2016; 7: 21753-21762
    PubMedGoogle Scholar